Iterum Therapeutics plc (ITRMF) Free Cash Flow (2017 - 2025)

Iterum Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$7.5 million for Q3 2025.

• In Q3 2025, Free Cash Flow fell 179.15% year-over-year to -$7.5 million; the TTM figure through Sep 2025 stood at -$19.5 million (up 44.77% YoY), while the FY2024 annual figure was -$26.8 million, up 31.95% from the prior year.
• Free Cash Flow for Q3 2025 stood at -$7.5 million, down from -$4.8 million in the prior quarter.
• The five-year high for Free Cash Flow was -$1.1 million in Q1 2021, with the low at -$13.1 million in Q1 2024.
• The 5-year median for Free Cash Flow is -$4.8 million (2025), against an average of -$6.1 million.
• The sharpest annual moves came in 2021 and 2022: Free Cash Flow soared 95.87% in 2021, then sank 200.8% in 2022.
• Iterum Therapeutics' Free Cash Flow stood at -$2.5 million in 2021, then plunged by 74.35% to -$4.3 million in 2022, then plunged by 197.98% to -$12.8 million in 2023, then soared by 66.86% to -$4.3 million in 2024, then slumped by 75.26% to -$7.5 million in 2025.
• Business Quant data shows ITRMF's Free Cash Flow at -$7.5 million in Q3 2025, -$4.8 million in Q2 2025, and -$3.1 million in Q1 2025.